Navigation Links
Vanda Pharmaceuticals to Present Data on Iloperidone at the 2007,American Psychiatric Association Annual Meeting

ROCKVILLE, Md., May 18, 2007 /PRNewswire-FirstCall/ -- Vanda Pharmaceuticals Inc. announced today that it will present four posters on iloperidone at the 160th American Psychiatric Association (APA) annual meeting which will be held at the San Diego Convention Center in San Diego, CA, from May 19 through May 24, 2007.

The following posters will be presented on May 22, 2007, 12:00 to 2:00 p.m. PDT, in the San Diego Convention Center (Sails Pavilion, Upper Level).

POSTER NR475 - Changes in Akathisia with Iloperidone, Risperidone, or Placebo Over the Course of an Acute Efficacy Trial (Peter Weiden, M.D. and Curt Wolfgang, Ph.D.)

POSTER NR476 - Iloperidone is Well Tolerated by Subjects with Renal or Hepatic Impairment in Single-Dose Clinical Pharmacokinetic Studies (Greg Sedek, M.D., Ph.D. and Curt Wolfgang, Ph.D.)

POSTER NR507 - A Pharmacokinetic (PK)-Pharmacodynamic (PD) Relationship Exists for Efficacy of Iloperidone, a Novel Investigational Atypical Antipsychotic Agent (Paolo Baroldi, M.D., Ph.D. and Curt Wolfgang, Ph.D.)

POSTER NR508 - Genotyping Facilitates Individualized Prediction of Pharmacokinetic Exposure of Iloperidone in Extensive and Poor CYP2D6 Metabolizers (Curt Wolfgang, Ph.D.)

ABOUT VANDA PHARMACEUTICALS INC.:

Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders. The company has three product candidates in clinical development. Vanda's lead product candidate, iloperidone, is a compound for the treatment of schizophrenia and bipolar disorder and has recently completed its Phase III program in schizophrenia. Vanda's second product candidate, VEC-162, is a compound for the treatment of sleep and mood disorders which is currently in Phase III for insomnia. Vanda's third product candidate, VSF-173, is a compound for the treatmen t of excessive sleepiness that is in a Phase II clinical trial. For more on Vanda Pharmaceuticals Inc., please visit www.vandapharma.com.

CONTACT: Steven A. Shallcross, Senior Vice President, Chief FinancialOfficer of Vanda Pharmaceuticals Inc., +1-240-599-4500, steven.shallcross@vandapharma.com

Web site: http://www.vandapharma.com//

Ticker Symbol: (NASDAQ-NMS:VNDA)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Related medicine technology :

1. Vanda Pharmaceuticals To Present Data on VEC-162 at SLEEP 2007, the Annual Meeting of the Associated Professional Sleep Societies
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
6. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
7. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
8. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... , Jan. 20, 2017  Ethicon Endo-Surgery, ... Megadyne Medical Products, Inc., a privately held ... markets electrosurgical tools used in operating rooms ... of Ethicon,s* advanced energy devices with Megadyne,s ... major step forward in Ethicon,s goal to ...
(Date:1/20/2017)... VAE, January 20, 2017 ... Bedarf an Nothilfe   Die internationale humanitäre Stadt ... Hilfsgüter zu schaffen   Seine Hoheit ... der VAE sowie Herrscher von Dubai ... Stadt der Hilfe (International Humanitarian City IHC) zu verdreifachen, ...
(Date:1/19/2017)... YORK , Jan. 19, 2017 The ... provides understanding and access to partnering deals and agreements ... - Trends in partnering deals - Top deals by ... stage of development, technology type The report provides ... entered into by the world,s leading healthcare companies. ...
Breaking Medicine Technology:
(Date:1/21/2017)... , ... January 21, 2017 , ... Seamild, the largest ... the futuristic vision of its owner and founder. As Oat is recognized globally as ... everybody he knows personally as he believes it is a move to sow the ...
(Date:1/21/2017)... ... 21, 2017 , ... In the United States, 20 million women and 10 ... they often feel shame for having struggled with an eating disorder as well as ... “Rising Strong in Life After an Eating Disorder” -- to be featured at this ...
(Date:1/20/2017)... (PRWEB) , ... January 20, 2017 , ... Source Vitál ... and 100 percent pure essential oils, announced the company had a successful visit to ... The annual ECRM event gives companies that work in the nutritional, sports and health ...
(Date:1/20/2017)... ... January 20, 2017 , ... International Protein, a company based out ... announced it attended the January ECRM trade show in Hilton Head, SC. , ... was determined to create a line of products that would elevate her fitness regime. ...
(Date:1/20/2017)... ... ... “The Angel”: a heartwarming and earnest tale of faith and believing ... “The Angel” is the creation of published author, Marjorie Lund-Fontaine, a former professional violinist, ... , When asked of her new book, Marjorie says, “‘The Angel’ was written as ...
Breaking Medicine News(10 mins):